Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 5/2015

01-05-2015 | Original Article

Significance of IL-1RA Polymorphism in Iranian Patients with Inflammatory Bowel Disease

Authors: Nasser Ebrahimi Daryani, Maryam Sadr, Shirin Moossavi, Sepideh Shahkarami, Samaneh Soltani, Elham Farhadi, Nima Rezaei

Published in: Digestive Diseases and Sciences | Issue 5/2015

Login to get access

Abstract

Background and Aim

Interleukin (IL)-1 family members play an important role in the pathogenesis of inflammatory bowel disease (IBD). There are conflicting results regarding the association of IL-1 gene cluster single nucleotide polymorphisms (SNPs) with IBD and its clinical features. The aim of this study was to examine IL-1α −889 C/T, IL-1β −511 C/T, IL-1β +3962 C/T, IL-1R Pst-I1970 C/T, and IL-1RA Mspa-I11100 C/T SNPs in Iranian patients.

Methods

In this study, SNPs of IL-1 family members were investigated in 75 patients with IBD (40 CD and 35 UC), using polymerase chain reaction with sequence-specific primers method.

Results

IL-1β −511 CC genotype was significantly less present in UC compared to controls, while IL-1RA Mspa-I11100 CC was significantly associated with both Crohn’s disease (CD) and ulcerative colitis (UC). IL-1α −889 TT genotype was more frequently associated with extraintestinal manifestations. A significant association was observed between IL-1β +3962 TT genotype and the disease activity in IBD. IL-1RA Mspa-I11100 CC was significantly less frequent in CD patients who need immunosuppressive therapy. IL-1RA Mspa-I11100 CT was associated with earlier age of onset in IBD, while TT genotype was associated with higher age of onset in IBD.

Conclusions

IL-1 SNPs seem to be associated with IBD and could affect the disease severity as well.
Literature
1.
2.
3.
4.
Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012;209:251–258.CrossRefPubMedCentralPubMed
5.
Chang J, Burkett PR, Borges CM, Kuchroo VK, Turka LA, Chang CH. MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci USA. 2013;110:2270–2275.CrossRefPubMedCentralPubMed
6.
Elkabets M, Ribeiro VS, Dinarello CA, et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40:3347–3357.CrossRefPubMedCentralPubMed
7.
Ostanin DV, Bhattacharya D. Myeloid-derived suppressor cells in the inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:2468–2477.CrossRefPubMed
8.
Ludwiczek O, Vannier E, Borggraefe I, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol. 2004;138:323–329.CrossRefPubMedCentralPubMed
9.
Dionne S, D’Agata ID, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol. 1998;112:435–442.CrossRefPubMedCentralPubMed
10.
Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut. 1990;31:686–689.CrossRefPubMedCentralPubMed
11.
Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn’s disease. Gut. 1989;30:835–838.CrossRefPubMedCentralPubMed
12.
Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94:174–181.CrossRefPubMedCentralPubMed
13.
Nasiri R, Amirzargar AA, Movahedi M, et al. Single-nucleotide polymorphisms of TNFA and IL1 in allergic rhinitis. J Investig Allergol Clin Immunol. 2013;23:455–461.PubMed
14.
Amirzargar A, Shahram F, Nikoopour E, et al. Proinflammatory cytokine gene polymorphisms in Behcet’s disease. Eur Cytokine Netw. 2010;21:292–296.PubMed
15.
Barkhordari E, Rezaei N, Ansaripour B, et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol. 2010;30:74–79.CrossRefPubMed
16.
Rezaei N, Amirzargar AA, Shakiba Y, Mahmoudi M, Moradi B, Aghamohammadi A. Proinflammatory cytokine gene single nucleotide polymorphisms in common variable immunodeficiency. Clin Exp Immunol. 2009;155:21–27.CrossRefPubMedCentralPubMed
17.
Mahdaviani SA, Rezaei N, Moradi B, Dorkhosh S, Amirzargar AA, Movahedi M. Proinflammatory cytokine gene polymorphisms among Iranian patients with asthma. J Clin Immunol. 2009;29:57–62.CrossRefPubMed
18.
Amirzargar AA, Rezaei N, Jabbari H, et al. Cytokine single nucleotide polymorphisms in Iranian patients with pulmonary tuberculosis. Eur Cytokine Netw. 2006;17:84–89.PubMed
19.
Amirzargar AA, Bagheri M, Ghavamzadeh A, et al. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet. 2005;32:167–171.CrossRefPubMed
20.
Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92–95.CrossRefPubMedCentralPubMed
21.
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.PubMed
22.
Amirzargar AA, Naroueynejad M, Khosravi F, et al. Cytokine single nucleotide polymorphisms in Iranian populations. Eur Cytokine Netw. 2008;19:104–112.PubMed
23.
Dominici R, Cattaneo M, Malferrari G, et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics. 2002;54:82–86.CrossRefPubMed
24.
Yamamoto-Furusho JK, Santiago-Hernández JJ, et al. Interleukin 1 β (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol. 2011;45:531–535.CrossRefPubMed
25.
Celik Y, Dagli U, Kilic MY, et al. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:559–565.CrossRefPubMed
26.
Nemetz A, Tóth M, García-González MA, et al. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001;49:644–649.CrossRefPubMedCentralPubMed
27.
Corleto VD, Pagnini C, Margagnoni G, et al. IL-1beta-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: an Italian population study and meta-analysis of European studies. Dig Liver Dis. 2010;42:179–184.CrossRefPubMed
28.
Tountas NA, Casini-Raggi V, Yang H, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 1999;117:806–813.CrossRefPubMed
29.
Queiroz DM, Oliveira AG, Saraiva IEM, et al. Immune response and gene polymorphism profiles in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15:353–358.CrossRefPubMed
30.
Li KS, Wang BY, Liu SY, Yao SP, Guo L, Mao DW. The combination of polymorphisms within MCP-1 and IL-1beta associated with ulcerative colitis. Int J Immunogenet. 2009;36:135–139.CrossRefPubMed
31.
Nohara H, Saito Y, Higaki S, et al. Polymorphisms of the IL-1beta and IL-1beta-inducible genes in ulcerative colitis. J Gastroenterol. 2002;37:107–110.CrossRefPubMed
32.
Ferreira AC, Almeida S, Tavares M, et al. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn’s disease. Inflamm Bowel Dis. 2005;11:331–339.CrossRefPubMed
33.
34.
Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics. 1999;49:527–531.CrossRefPubMed
35.
Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, et al. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013;69:431–438.CrossRefPubMed
36.
Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, van Deventer SJ. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut. 1998;43:33–39.CrossRefPubMedCentralPubMed
37.
Bouma G, Crusius JB, García-González MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999;115:294–300.CrossRefPubMedCentralPubMed
38.
Nemetz A, Köpe A, Molnár T, et al. Significant differences in the interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:175–179.CrossRefPubMed
39.
Hacker UT, Bidlingmaier C, Gomolka M, et al. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms. Eur J Clin Invest. 1998;28:214–219.CrossRefPubMed
40.
Bioque G, Crusius JB, Koutroubakis I, et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol. 1995;102:379–383.CrossRefPubMedCentralPubMed
41.
Hacker UT, Gomolka M, Keller E, et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut. 1997;40:623–627.CrossRefPubMedCentralPubMed
42.
43.
Nohara H, Inoue N, Hibi T, Okita K, Hinoda Y. Association between the interleukin-1 receptor antagonist polymorphism and ulcerative colitis with younger age at diagnosis. Immunol Lett. 2003;90:53–57.CrossRefPubMed
44.
Craggs A, West S, Curtis A, et al. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand J Gastroenterol. 2001;36:1173–1178.CrossRefPubMed
45.
Vijgen L, Van Gysel M, Rector A, et al. Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. Genes Immun. 2002;3:400–406.CrossRefPubMed
46.
Carter MJ, di Giovine FS, Jones S, et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut. 2001;48:461–467.CrossRefPubMedCentralPubMed
47.
Bersudsky M, Luski L, Fishman D, et al. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut. 2014;63:598–609.CrossRefPubMed
48.
Rider P, Carmi Y, Guttman O, et al. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835–4843.CrossRefPubMed
49.
Guler R, Parihar SP, Spohn G, Johansen P, Brombacher F, Bachmann MF. Blocking IL-1alpha but not IL-1beta increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine. 2011;29:1339–1346.CrossRefPubMed
50.
Kimura R, Nishioka T, Soemantri A, Ishida T. Cis-acting effect of the IL1B C-31T polymorphism on IL-1 beta mRNA expression. Genes Immun. 2004;5:572–575.CrossRefPubMed
51.
Chen H, Wilkins LM, Aziz N, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet. 2006;15:519–529.CrossRefPubMed
52.
Di Renzo L, Bigioni M, Del Gobbo V, et al. Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels. Pharmacol Res. 2007;55:131–138.CrossRefPubMed
53.
Schulte CM, Dignass AU, Goebell H, Röher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909–920.CrossRefPubMed
54.
Carter MJ, Di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology. 2001;121:805–811.CrossRefPubMed
55.
Aisenberg J, Legnani PE, Nilubol N, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004;99:432–441.CrossRefPubMed
56.
Heresbach D, Alizadeh M, Dabadie A, et al. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol. 1997;92:1164–1169.PubMed
Metadata
Title
Significance of IL-1RA Polymorphism in Iranian Patients with Inflammatory Bowel Disease
Authors
Nasser Ebrahimi Daryani
Maryam Sadr
Shirin Moossavi
Sepideh Shahkarami
Samaneh Soltani
Elham Farhadi
Nima Rezaei
Publication date
01-05-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3457-z

Other articles of this Issue 5/2015

Digestive Diseases and Sciences 5/2015 Go to the issue

Editorial

Bregs in Chronic HBV: Is It Time for Bragging Rights?

Editorial

Connecting the Dots Between Gastrointestinal Motility and Symptoms Using Wireless Motility Capsule Testing

Review

Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease

Original Article

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Review

Recent Advances in Cirrhotic Cardiomyopathy

Original Article

Lack of Familial Aggregation in Chronic Constipation Excluding Irritable Bowel Syndrome: A Population-Based Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits